PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 27, issue 12, 2009

Cost Effectiveness of Herpes Zoster Vaccine in Canada pp. 991-1004

Mehdi Najafzadeh, Carlo Marra, Eleni Galanis and David Patrick

Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster pp. 1005-1016

Tracy Lieu, G. Ray, Ismael Ortega-Sanchez, Ken Kleinman and Donna Rusinak

Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials pp. 1017-1029

Aline Gauthier, Andrea Manca and Susan Anton

Volume 27, issue 11, 2009

Cost Effectiveness in Low- and Middle-Income Countries pp. 903-917

Samuel Shillcutt, Damian Walker, Catherine Goodman and Anne Mills

Barriers to Generalizability of Health Economic Evaluations in Latin America and the Caribbean Region pp. 919-929

Federico Augustovski, Cynthia Iglesias, Andrea Manca, Michael Drummond, Adolfo Rubinstein and Sebastián Martií

Volume 27, issue 10, 2009

Economic Evaluation and Cost-Effectiveness Thresholds pp. 797-806

John Vernon, Robert Goldberg and Joseph Golec

Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective pp. 873-886

Peng Liubao, Wan Xiaomin, Tan Chongqing, Jon Karnon, Chen Gannong, Li Jianhe, Cui Wei, Luo Xia and Cao Junhua

Volume 27, issue 8, 2009

Estimating Drug Costs in Economic Evaluations in Ireland and the UK pp. 635-643

Dyfrig Hughes, Lesley Tilson and Michael Drummond

Economic Burden of Follicular Non-Hodgkin’s Lymphoma pp. 657-679

Talia Foster, Jeffrey Miller, Mark Boye and Mason Russell

Volume 27, issue 7, 2009

Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines pp. 533-545

Natasha Stout, Amy Knudsen, Chung Kong, Pamela McMahon and G. Gazelle

Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease pp. 609-621

Andrew Yu, Scott Johnson, Si-Tien Wang, Pavel Atanasov, Jackson Tang, Eric Wu, Jingdong Chao and Parvez Mulani

Volume 27, issue 5, 2009

The Future Costs, Risks and Rewards of Drug Development pp. 355-363

Joseph Cook, Graeme Hunter and John Vernon

The Cost of Dementia in Europe pp. 391-403

Linus Jönsson and Anders Wimo

Utility Assessment in Patients with Mental Disorders pp. 405-419

Hans-Helmut König, Oliver Günther, Matthias Angermeyer and Christiane Roick

Volume 27, issue 4, 2009

Economic and Human Costs of Restless Legs Syndrome pp. 267-279

Thomas Reinhold, Falk Müller-Riemenschneider, Stefan Willich and Bernd Brüggenjürgen

Reviewing the Cost Effectiveness of Rotavirus Vaccination pp. 281-297

Joke Bilcke and Philippe Beutels

Cost Effectiveness of Drug-Eluting Stents In Belgian Practice pp. 313-327

Mattias Neyt, Chris Laet, Annemieke Ridder and Hans Brabandt

Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder pp. 329-339

Laura Pizzi, Amy Talati, Eric Gemmen, Naomi Dahl, Thomas Bunz and Peter Sand

Volume 27, issue 3, 2009

The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone pp. 221-230

Peter Lindgren, Martin Buxton, Thomas Kahan, Neil Poulter, Björn Dahlöf, Peter Sever, Hans Wedel and Bengt Jönsson

Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium pp. 231-245

Lieven Annemans, Vanessa Rémy, James Oyee and Nathalie Largeron

Cost-Utility Analysis of Varenicline, an Oral Smoking-Cessation Drug, in Japan pp. 247-261

Ataru Igarashi, Hiroki Takuma, Takashi Fukuda and Kiichiro Tsutani

Volume 27, issue 2, 2009

Controlling Cervical Cancer pp. 91-93

Maurizio Bonati and Silvio Garattini

Neuropathic Pain pp. 95-112

Alec O’Connor

Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine pp. 127-147

Fawziah Marra, Karine Cloutier, Bridgette Oteng, Carlo Marra and Gina Ogilvie

Comparison of Markov Model and Discrete-Event Simulation Techniques for HIV pp. 159-165

Kit Simpson, Alvin Strassburger, Walter Jones, Birgitta Dietz and Rukmini Rajagopalan

Volume 27, issue 1, 2009

Statin Therapy in Rheumatoid Arthritis pp. 25-37

Nick Bansback, Roberta Ara, Sue Ward, Aslam Anis and Hyon Choi

Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin’s Lymphoma pp. 55-68

Philippe Fagnoni, Noel Milpied, Samuel Limat, Eric Deconinck, Virginie Nerich, Charles Foussard, Philippe Colombat, Jean-Luc Harousseau and Marie-Christine Woronoff-Lemsi

Estimating the Cost of Diabetes Mellitus-Related Events from Inpatient Admissions in Sweden Using Administrative Hospitalization Data pp. 81-90

Ulf-G. Gerdtham, Philip Clarke, Alison Hayes and Soffia Gudbjornsdottir

Volume 26, issue 12, 2008

Measuring US Pharmaceutical Industry R&D Spending pp. 1005-1017

Joseph Golec and John Vernon

Management and Prevention of Diabetic Foot Ulcers and Infections pp. 1019-1035

Ivy Chow, Elkin Lemos and Thomas Einarson

A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy pp. 1045-1064

Alec O’Connor, Katia Noyes and Robert Holloway

Volume 26, issue 11, 2008

The Impact of Influenza on Working Days Lost pp. 911-924

Martin Keech and Paul Beardsworth

A Review of Health-Utility Data for Osteoarthritis pp. 925-935

Hirsch Ruchlin and Ralph Insinga

A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B pp. 937-949

D. Spackman and David Veenstra

Economic Impact and Long-Term Graft Outcomes of Mycophenolate Mofetil Dosage Modifications Following Gastrointestinal Complications in Renal Transplant Recipients pp. 951-967

Gerardo Machnicki, Jean-Francois Ricci, Daniel Brennan and Mark Schnitzler

Escitalopram and Duloxetine in Major Depressive Disorder pp. 969-981

Alan Wade, Jose Luis Fernandez, Clément François, Karina Hansen, Natalya Danchenko and Nicolas Despiege

Volume 26, issue 8, 2008

Assessing the Impact of Global Price Interdependencies pp. 649-659

Anke Richter

Conducting Discrete Choice Experiments to Inform Healthcare Decision Making pp. 661-677

Emily Lancsar and Jordan Louviere

Volume 26, issue 7, 2008

Future Drug Prices and Cost-Effectiveness Analyses pp. 589-602

Martin Hoyle

Generic Entry, Reformulations and Promotion of SSRIs in the US pp. 603-616

Haiden Huskamp, Julie Donohue, Catherine Koss, Ernst Berndt and Richard Frank

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK pp. 617-627

Ray Gani, Gavin Giovannoni, David Bates, Belinda Kemball, Steve Hughes and John Kerrigan

Volume 26, issue 6, 2008

Economic Burden of Heart Failure in the Elderly pp. 447-462

Lawrence Liao, Larry Allen and David Whellan

Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis pp. 513-536

Dirk Mueller, Eva Weyler and Afschin Gandjour

Volume 26, issue 4, 2008

Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis pp. 311-328

Simon Kreck, Jochen Klaus, Reiner Leidl, Christian Tirpitz, Alexander Konnopka, Herbert Matschinger and Hans-Helmut König

Volume 26, issue 3, 2008

Cost-Effectiveness Analyses of Vaccination Programmes pp. 191-215

Sun-Young Kim and Sue Goldie

Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens pp. 217-234

Jeremy Chancellor, Samuel Aballéa, Alison Lawrence, Rob Sheldon, Sandrine Cure, Juliette Plun-Favreau and Nick Marchant

Community and Patient Values for Preventing Herpes Zoster pp. 235-249

Tracy Lieu, Ismael Ortega-Sanchez, G. Ray, Donna Rusinak, W. Yih, Peter Choo, Irene Shui, Ken Kleinman, Rafael Harpaz and Lisa Prosser

Volume 26, issue 1, 2008

Cost-Effectiveness Analyses of Hepatitis A Vaccine pp. 17-32

Andrea Anonychuk, Andrea Tricco, Chris Bauch, Ba’ Pham, Vladimir Gilca, Bernard Duval, Ava John-Baptiste, Gloria Woo and Murray Krahn

Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas pp. 33-44

Gabriel Rogers, Ruth Garside, Stuart Mealing, Martin Pitt, Rob Anderson, Matthew Dyer, Ken Stein and Margaret Somerville

Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration pp. 57-73

Alan Cruess, Gergana Zlateva, Xiao Xu, Gièle Soubrane, Daniel Pauleikhoff, Andrew Lotery, Jordi Mones, Ronald Buggage, Caroline Schaefer, Tyler Knight and Thomas Goss